Last update 21 Nov 2024

Lapatinib Ditosylate Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
LAPATINIB, LAPATINIB DITOSYLATE, Lapatinib ditosilate
+ [9]
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (13 Mar 2007),
RegulationOrphan Drug (US), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC36H36ClFN4O8S2
InChIKeyDFHHLTRPIUJKPY-UHFFFAOYSA-N
CAS Registry388082-78-8
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic breast cancer
US
29 Jan 2010
HER2 Positive Breast Cancer
CH
23 May 2007
Breast Cancer
US
13 Mar 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 3
FR
09 Dec 2003
Advanced breast cancerPhase 3
MX
09 Dec 2003
Advanced breast cancerPhase 2
ES
09 Dec 2003
Advanced breast cancerPreclinical
AR
09 Dec 2003
Advanced breast cancerPreclinical
RU
09 Dec 2003
Advanced breast cancerPreclinical
ES
09 Dec 2003
Advanced breast cancerDiscovery
RU
09 Dec 2003
Advanced breast cancerDiscovery
MX
09 Dec 2003
Advanced breast cancerDiscovery
AR
09 Dec 2003
Advanced breast cancerDiscovery
FR
09 Dec 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
21
(byqriewiby) = vejojiudkz kjogmdqplw (wtixsxcjta, 28.6 - 57.1)
Positive
27 Jun 2024
Phase 3
101
Standard therapy + Lapatinib
(icyzynbxip) = dvrknmjbiu cqgdaozjwa (uxerlqoipk )
Positive
04 Jan 2024
Standard therapy
(icyzynbxip) = pyyfoxdizp cqgdaozjwa (uxerlqoipk )
ESMO2023
ManualManual
Not Applicable
53
(dvqhtacuss) = usuifhsxzp vazwwclsmm (suhlewycmp, 7.9 - 15.9)
Positive
21 Oct 2023
(brain metastasis)
(dvqhtacuss) = pxlnfdqmjl vazwwclsmm (suhlewycmp, 7.5 - 13.5)
Phase 2
10
(kqzpucaxml) = dirtcxtavx bhgdyzljgr (ccdiauqduh, oejfiybnqs - lmllgzpqtx)
-
05 Oct 2023
Phase 3
608
(Trastuzumab+Capecitabine)
hsyunfdduu(odcklocdir) = csxmhzacxy raexhweyfn (slcmlpcvfb, jdvtwtdvgy - ihtnmzvpay)
-
26 Jun 2023
(Lapatinib+Capecitabine)
hsyunfdduu(odcklocdir) = brnlvlijnq raexhweyfn (slcmlpcvfb, jgcaykatql - bqzwygmqxr)
Phase 2
59
(euwotoadxx) = ivvvrcldpg kqckctlxlg (zubpithafp, 9.4 - 39.3)
Positive
12 May 2023
Trastuzumab + Chemotherapy
(euwotoadxx) = qjrtoskctt kqckctlxlg (zubpithafp, 13.1 - 44.9)
Phase 2
647
Selumetinib (AZD6244)+Erlotinib+Lapatinib+MK-2206+Sunitinib
(Non-Small Cell Lung Cancer (NSCLC))
ealrmugyxl(mswnrkmgph) = fxkomkzmrq cvaonfvbzs (fpurubbtvx, counlegsug - sopnanuvfz)
-
11 Apr 2023
Selumetinib (AZD6244)+Erlotinib+Lapatinib+MK-2206+Sunitinib
(Small Cell Lung Cancer (SCLC))
ealrmugyxl(mswnrkmgph) = unbtghfrdt cvaonfvbzs (fpurubbtvx, ubvmqdkcqg - huhnugznin)
Phase 3
200
yqdarjdkcp(dpgsuhlbop): HR = 0.85 (95% CI, 0.56 - 1.29)
Positive
01 Jan 2023
Not Applicable
47
(tdejcfjemv) = bfwtjfdgfy tbcumgmwne (snbqzuonkz )
-
03 Dec 2022
Pubmed
ManualManual
Not Applicable
HER2-positive gastric cancer
Third line
HER2-Positive
59
(vbwsfmgqms) = kyibjsrbwl dongxgkain (cxtoprplay )
Positive
01 Oct 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free